Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
UNITED THERAPEUTICS CORPORATION v. SANDOZ, INC.
Case Number:
3:12-cv-01617
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
September 30, 2015
Sandoz, UTC Settle Generic Remodulin Patent Suit
United Therapeutics Corp. has given Sandoz Inc. a non-exclusive license to manufacture and sell a generic version of its hypertension drug Remodulin, ending more than three years of patent litigation, UTC announced Wednesday.
-
August 29, 2014
Sandoz's Remodulin Generic Infringes UTC Patent, Judge Says
A New Jersey federal judge on Friday found that Sandoz Inc.'s proposed generic version of the hypertension drug Remodulin infringes one of two United Therapeutics Corp. patents, rejecting Sandoz's contention that contested claims of both patents are invalid.
-
June 03, 2014
Sandoz Gets Claims Nixed In UTC's Generic Remodulin Fight
A New Jersey federal judge overseeing United Therapeutics Corp.'s patent litigation over Sandoz Inc.'s proposed generic version of hypertension drug Remodulin, on Monday tossed both parties' claims regarding one of the three at-issue patents.
-
April 16, 2014
Sandoz Can't Pare Claim From Generic Remodulin Suit
Sandoz Inc. can't trim a claim from a patent suit over a proposed generic version of United Therapeutics Corp.'s hypertension drug Remodulin, after a New Jersey federal judge on Wednesday found a basis for UTC's claim that Sandoz induced physicians to infringe the patent.